Neon Therapeutics is a clinical-stage immuno-oncology company and focused on the field of neoantigen-targeted therapies, engaged in transforming the treatment of cancer by directing the immune system towards neoantigens. Co.'s neoantigen vaccine, NEO-PV-01, is custom-designed and manufactured based on the mutational fingerprint of each individual patient. Co.'s neoantigen T cell therapy, NEO-PTC-01, consists of various T cell populations that are generated to target each individual patient's set of neoantigens. Co.'s product candidate, NEO-SV-01, is a neoantigen vaccine for the treatment of a genetically defined subset of estrogen-receptor-positive breast cancer. We show 11 historical shares outstanding datapoints in our coverage of NTGN's shares outstanding history.
Understanding the changing numbers of NTGN shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like NTGN versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching NTGN by allowing them to research NTGN shares outstanding history
as well as any other stock in our coverage universe. |
Free NTGN Email Alerts:
Video: Shares Outstanding Importance
